Gain detailed insights into the trading activity of Congress members for DexCom on our government trades page. Stay updated on how elected officials are investing in DXCM.

DexCom - Government Trades

DexCom

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.

Earnings

News

Health Care

Markets

Analyst Ratings

Trading Ideas

General

DXCM

DexCom, Abbott to Launch First FDA Cleared OTC CGMs

Chatgpt,Chat,With,Ai,Or,Artificial,Intelligence,Technology.,Businessman,Using

AAPL

AMZN

GOOG

MSFT

NHNCF

QCOM

SFTBY

SSNLF

TSLA

What&#39;s New In the Consumer Tech World Last Week? News That You Should Know (June 9-June 15, 2024)

Apple Watch Photo by Anna Hoychuk on Shutterstock

Tech

Media

Dexcom Inc. has enabled direct Apple Watch connectivity for its G7 glucose monitor, allowing users to access real-time glucose data without needing an iPhone.

Apple Watch Now Directly Syncs With Dexcom&#39;s G7 Glucose Monitor

Aon - logo

Intraday Update

Movers

ACCD

ACMR

ACON

AILE

AIRE

ALSN

APPF

ARCB

ATXI

BACK

BDRX

CGEM

CSSE

ELWS

EXPO

FCUV

FRGT

GOOGL

ICLK

INTC

KNSL

KTOS

Kintara Therapeutics, Inc. - Common Stock

KTRA

Eaton Vance Massachusetts Municipal Income Trust

NIVF

NUWE

NWGL

ODFL

PCSA

PEGY

RERE

ROKU

SAIA

SBFM

SGBX

SKIL

SLCA

SNAP

TEAM

TNET

TVGN

VINC

WORX

ZVSA

Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Google Parent Alphabet

Pre-Market Outlook

Nuveen Insured California Premium Fund Ii

Why Alphabet Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket

intel laptop manufacturing

TDOC

Intel Reports Weak Sales, Joins Boyd Gaming, Atlassian And Other Big Stocks Moving Lower In Friday&#39;s Pre-Market Session

Short Ideas

Insider Trades

The Nasdaq 100 closed lower by around 0.1% on Thursday. Investors, meanwhile, focused on some notable insider trades.

Micron, Dropbox And 2 Other Stocks Insiders Are Selling

Analyst Color

Initiation

DexCom Is &#39;Expanding Rapidly&#39; With Multi-Year Runway Ahead, Bullish Analyst Says

Long Ideas

PLTR

On CNBC’s &#34;Halftime Report Final Trades,&#34;  Jenny Harrington of Gilman Hill Asset Management named  SL Green Realty Corp.

Palantir Technologies, SL Green Realty And A Healthcare Stock On CNBC&#39;s &#39;Final Trades&#39;

Dexcom Stelo-Company

Large Cap

FDA greenlights DexCom&#39;s Stelo, the first OTC continuous glucose monitor for non-insulin-dependent diabetics. Competitive pricing, potential HSA benefits, and market expansion make it a significant player in the CGM space.

FDA Approval For DexCom&#39;s Stelo Opens Continuous Glucose Monitoring To Masses, Analyst Expects Competitive Pricing Against Abbott&#39;s

DexCom Inc

DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) has outperformed the market over the past 5 years by 11.92% on an annualized basis producing an average annual return of 25.21%. Currently, DexCom has a market capitalization of $45.21 billion. 
Buying $1000 In DXCM: If an investor had bought $1000 of DXCM stock 5 years ago, it would be worth $3,122.92 today based on a price of $113.69 for DXCM at the time of writing.
<h3>DexCom's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1720211416_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning DexCom Stock In The Last 5 Years

DexCom Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dxcm#NASDAQ">DXCM</a>) and Abbott Laboratories (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abt#NYSE">ABT</a>)&nbsp;are likely to launch their first over-the-counter (OTC) continuous glucose monitors (CGMs) in the coming months of 2024.
Dexcom&#39;s Stelo and Abbott&#39;s Lingo &amp; Libre Rio received FDA clearance in March and June this year, respectively, and now they are up for launch in the coming months of 2024. These devices use the same hardware as past CGMs but are intended for people who do not take insulin.
The new devices are likely to allow the companies to reach about 25 million people in the United States with Type 2 diabetes who do not take insulin, 15 million people who have been diagnosed with pre-diabetes and an estimated 85 million people who have undiagnosed pre-diabetes. This represents a significant market opportunity for both companies.
<h3>More on the Launch</h3>
With Stelo CGM, Dexcom is likely to target people with Type 2 diabetes who do not take insulin. However, Stelo can also be used by non-diabetic people, thanks to a broad label from the FDA. Abbott, on the other hand, will split its OTC CGM into two sensors: Lingo, which is intended for people who do not have diabetes, and Libre Rio, which will compete more directly with Dexcom for Type 2, non-insulin users.
Abbott is offering two different OTC CGMs as the company believes that &quot;there&#39;s no one size fits all approach to managing care.&quot; Per the company, people living with diabetes might want features for insulin management, medication tracking and sharing data with a provider or caregiver. However, Dexcom&#39;s Stelo is the only OTC CGM that is intended for people with Type 2 diabetes. The company expects that a large number of non-diabetic people will try the device.
Dexcom is likely to plan a late August launch of its Stelo sensor. The company is looking forward to first selling the device online, which can prove beneficial for the company to learn more about users and their buying patterns. Abbott also intends to launch an e-commerce website this summer to offer its wellness-focused Lingo device. The company has not yet revealed any schedule for Libre Rio.
On the pricing front, both companies have not disclosed pricing for the upcoming products. Dexcom&#39;s Stelo is likely to be competitive with other cash-pay products. In the United Kingdom, where Abbott first launched its Lingo device, the company charges roughly around $150 a month.
<h3>More on Dexcom&#39;s Stelo</h3>
Dexcom announced the FDA clearance of its Stelo OTC glucose biosensor to consumers without a prescription in March 2024. The G7, the company&#39;s most recent CGM sensor, is presently prescribed. With Stelo&#39;s approval for non-prescription use, people without insurance coverage for CGM would have even easier access to state-of-the-art CGM technology.
The development of Stelo, which was made possible by the Dexcom G7 makers, took into consideration the special requirements of adults with Type 2 diabetes who are over 18 and do not need insulin. The gadget is a tiny wearable sensor that is placed on the back of the upper arm and sends data on blood sugar levels straight to a user&#39;s smartphone.
Stelo&#39;s software is designed to onboard people who have never used a CGM, as well as to educate them about what blood glucose means and how changes throughout the day are normal. The product&#39;s main purpose is to help people manage their diet and activities to lower their average glucose.
<h3>More on Abbott&#39;s OTC CGMs</h3>
Abbott announced the FDA clearance of its Lingo &amp; Libre Rio CGMs, which are based on Abbott&#39;s world-leading FreeStyle Libre&nbsp;CGM technology, in June 2024. The newly cleared systems have been intentionally designed to meet different needs: Lingo for consumers who want to better understand and improve their health and wellness, and&nbsp;Libre Rio&nbsp;for adults with Type 2 diabetes who do not use insulin and typically manage their diabetes through lifestyle modifications.
Abbott&#39;s consumer bio-wearable, Lingo, is designed for consumers 18 years and older who are looking to improve their overall health and wellness. Lingo is set to track glucose and provide personalized insights and customized coaching to help people create healthy habits, retrain their metabolism and improve their overall well-being. &nbsp;The Lingo system combines a biosensor that is worn on the upper arm for 14 days&nbsp;and continuously streams glucose data to a coaching application on a smartphone, translating the body&#39;s language and giving insights on the person&#39;s reaction to food, exercise and life&#39;s daily stressors.
Libre Rio&nbsp;is Abbott&#39;s first OTC CGM system for people with diabetes in the United States. It is designed for people aged 18 and older with Type 2 diabetes who do not use insulin and typically manage their diabetes through lifestyle modifications.&nbsp;Libre Rio&nbsp;is the first OTC CGM system with a measurement range of 40-400 mg/dL, allowing for the measurement of extremely low or high glucose events.
<h3>Expected Revenue Growth</h3>
Dexcom has estimated that Stelo is likely to bring $40 million in sales this financial year. Even though Abbott has refused to provide any sales estimates for its upcoming devices, the company anticipates its diabetes business to reach $10 billion in revenues by 2028. A better commercialization plan and a strong sales team should help the companies gain market share in this new segment.
Abbott has significantly higher resources with an extensive presence in healthcare product markets. This is expected to help the company gain an advantage over DexCom as commercialization of Stelo and Lingo begins this year. However, DexCom has significant success with its CGM devices in the United States, and a similar trend may follow in the OTC glucose sensor market amid competition from a larger device maker. The companies will likely provide updates on their OTC glucose sensors during their next earnings call.
<h3>Industry Prospects</h3>
Per a report by MarketsandMarkets, the global digital diabetes management market was estimated to be $18.9 billion in 2023 and is expected to reach $35.8 billion by 2028 at a growth rate of 13.6%.
The market is being driven by escalating diabetes care solutions and technological developments that have made it possible to introduce highly adaptable solutions. Other significant drivers include the increasing popularity of the use of connected devices and apps as well as the growing adoption of cloud-based solutions.
<h3>Price Performance</h3>
In the past six months, DXCM&#39;s shares have lost 10.5%, and ABT&#39;s shares have plunged 7.6% against the medical sector&#39;s &nbsp;2.4% growth. The S&amp;P 500 has increased 18.7% in the same time frame.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/be/70367.jpg?v=1648397754" />
Image Source: Zacks Investment Research
<h3>Zacks Rank &amp; Other Stocks to Consider</h3>
DXCM presently carries a Zacks Rank #2 (Buy).
A couple of other top-ranked stocks in the broader medical space that have announced quarterly results are&nbsp;DaVita&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dva#NYSE">DVA</a>) and Ecolab&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ecl#NYSE">ECL</a>).
DaVita, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.6%. DVA&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 29.4%.
DaVita&#39;s shares have gained 44% compared with the&nbsp;industry&#39;s 20.4% growth in the past year.
Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.3%. ECL&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 1.7%.
Ecolab&#39;s shares have gained 33.8% against the&nbsp;industry&#39;s 9.3% decline in the past year.
<a href="https://www.zacks.com/stock/news/2297344/dexcom-dxcm-abbott-to-launch-first-fda-cleared-otc-cgms?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2297344">To read this article on Zacks.com click here.</a>

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.dexcom.com%2Fen-us&amp;esheet=54083521&amp;newsitemid=20240620606764&amp;lan=en-US&amp;anchor=DexCom%2C+Inc.&amp;index=1&amp;md5=c3e6f8d27539cdbced17cee6ca26dbd9">DexCom, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase its expanding focus on Dexcom CGM use among people with Type 2 diabetes, the launch of the Omnipod 5 Automated Insulin Delivery System with Dexcom G7 and its relentless commitment to innovation at the 84th&nbsp;Scientific Sessions of the American Diabetes Association conference held June 21&ndash;24, 2024, in Orlando.
Dexcom: The CGM brand for people with Type 2 diabetes, prediabetes and those using GLP-1s
This year at ADA, Dexcom is presenting more data on Dexcom CGM use among people with Type 2 diabetes than ever before. This data shows clinically meaningful decreases in A1C and increases in time in range for Dexcom CGM users with Type 2 diabetes both on insulin and not on insulin.3-5
Additionally, studies presented at the conference demonstrate Dexcom CGM use by people with Type 2 diabetes not on insulin is associated with improved A1C independent of anti-diabetes medication, and there may be further benefits of CGM for this population when used in combination with therapies such as GLP-1s.1&nbsp;As the use of GLP-1s continues to grow, data continues to show people with Type 2 diabetes on GLP-1s are more likely to use CGM after starting the medication.2
Going beyond Type 2 diabetes, another study presented at ADA demonstrates Dexcom CGM is a valuable behavior modification tool for people with prediabetes.6&nbsp;In this study, Dexcom CGM use was associated with improved self-reported psychosocial health and self-care behaviors in participants with prediabetes including perceived benefits related to eating, physical activity, weight, blood pressure, worry, energy levels and healthcare provider interactions.
&quot;As the evidence of the benefits of CGM use by people with Type 2 diabetes and prediabetes continues to grow, Dexcom is uniquely positioned to address their needs through our portfolio of products,&quot; said Jake Leach, executive vice president and chief operating officer at Dexcom. &quot;Dexcom G7 is the most accurate and affordable7&nbsp;CGM system available for people with Type 1 diabetes and Type 2 diabetes who use insulin, and when Stelo by Dexcom launches in late August, we will have a glucose biosensor available for purchase without a prescription designed specifically for people with Type 2 diabetes not using insulin.&quot;
Dexcom: The clear choice for automated insulin delivery
Dexcom further solidified its position as the industry leader in connectivity this morning with Insulet&#39;s announcement commencing the launch of the Omnipod 5 with Dexcom G7. Beginning today, new Omnipod 5 users can experience the benefits of the only tubeless AID system connected to Dexcom G7, the most accurate CGM7&nbsp;powering AID systems. Dexcom G7 will be available for existing Omnipod 5 users in the U.S. later this year.
Dexcom CGM currently connects to more AID pump options than any other CGM brand in the U.S.; the iLet Bionic Pancreas insulin pump, the Tandem pump portfolio (Tandem Mobi and t:slim X2 insulin pumps), and now Omnipod 5. For those seeking more information about the recent integration of Dexcom G7 and the Tandem Mobi insulin pump, there will be an evening education event during ADA on June 22, 2024, from 6-8 p.m.&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcvent.me%2Fg23gAO&amp;esheet=54083521&amp;newsitemid=20240620606764&amp;lan=en-US&amp;anchor=Registration&amp;index=2&amp;md5=e02b5a90235c488ea55edca8528ce44b">Registration</a>&nbsp;is open to U.S. healthcare provider attendees.
With hundreds of thousands of users now connected to insulin pumps, pens and digital health apps, Dexcom is the undisputed leader in CGM connectivity.
Dexcom: A relentless commitment to innovation and customer experience
For 25 years, Dexcom has been the pioneer in continuous glucose monitoring, continually innovating on behalf of people with diabetes. The release of new app updates this month has further improved the features and user experience of Dexcom G7, the world&#39;s most accurate CGM system.7
Dexcom G7 is now the first and only CGM with Direct to Apple Watch connectivity, allowing users to leave their iPhone&nbsp;&Dagger;&nbsp;behind and manage diabetes hands-free.​ It&#39;s now the first and only CGM with automated activity and medication logging, helping users visualize how activity and medications affect glucose in real-time. And with enhanced Bluetooth with Rapid Reconnect, Dexcom G7 now has&nbsp;65%&nbsp;farther&nbsp;&sect;,8&nbsp;Bluetooth range and quicker reconnection when signal is lost, keeping users connected longer.​

Dexcom Showcases Expanded Focus on Type 2 Diabetes at ADA Conference

DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) has outperformed the market over the past 5 years by 12.09% on an annualized basis producing an average annual return of 25.32%. Currently, DexCom has a market capitalization of $46.34 billion. 
Buying $1000 In DXCM: If an investor had bought $1000 of DXCM stock 5 years ago, it would be worth $2,994.48 today based on a price of $116.53 for DXCM at the time of writing.
<h3>DexCom's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1718656226_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In DexCom 5 Years Ago Would Be Worth Today

Billionaire entrepreneur Mark Cuban thinks that efforts by the U.S. government and investors in proprietary large-language models to regulate artificial intelligence (AI) will end up giving the lead in this <a href="https://www.benzinga.com/news/24/06/39245450/mark-cuban-warns-us-ai-regulations-could-give-china-the-edge-after-openais-sora-faces-new-threat-fro" target="_blank" rel="noreferrer noopener">critical field to Chinese companies</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/06/39246035/linkedin-vp-aneesh-raman-stresses-importance-of-soft-skills-in-ai-era-engaging-with-ai-is-not-a-digi" rel="noreferrer noopener">LinkedIn VP Aneesh Raman Stresses Importance Of Soft Skills In AI Era: &#8216;&#8230;Engaging With AI Is Not A Digital Skill Set. It&#8217;s A Communication Skill Set&#8217;</a>
A series of data breaches at a $20 billion internet company co-owned by Japan&#8217;s SoftBank Corp (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBY#OTC">SFTBY</a>) and South Korea&#8217;s Naver (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NHNCF#OTC">NHNCF</a>) is causing diplomatic <a href="https://www.benzinga.com/news/24/06/39266985/data-leak-in-masayoshi-sons-softbank-backed-internet-company-causes-strain-in-japan-south-korea-rela" target="_blank" rel="noreferrer noopener">tensions between the two nations</a>.
Read: <a href="https://www.benzinga.com/general/gaming/24/06/39300006/fromsoftwares-miyazaki-admits-room-for-improvement-if-players-rely-on-guides-in-elden-ring" target="_blank" rel="noreferrer noopener">FromSoftware&#8217;s Miyazaki Admits &#8216;Room For Improvement&#8217; If Players Rely On Guides In Elden Ring</a>
The launch of a new gossip app,&nbsp;Fizz, at a Vermont high school has reportedly led to widespread bullying and controversy, reigniting concerns about the&nbsp;<a href="https://www.benzinga.com/news/24/06/39251360/new-gossip-app-fizz-leads-to-widespread-high-school-bullying-raises-concerns-over-teen-anxiety-repor" target="_blank" rel="noreferrer noopener">impact of social media&nbsp;on teen mental health</a>.
Vrio Corporation, the parent company of DIRECTV Latin America and Sky Brasil, has partnered with&nbsp;Amazon.com, Inc&#8217;s. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) Project Kuiper to offer satellite broadband in <a href="https://www.benzinga.com/markets/latin-america/24/06/39306491/amazons-project-kuiper-partners-with-vrio-corporation-to-deliver-satellite-broadband-in-7-s" target="_blank" rel="noreferrer noopener">seven South American countries</a>.
Gaming
Microsoft Corp&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) revealed during Xbox Games Showcase and the Call of Duty Direct event that &#8220;Call of Duty: Black Ops 6&#8221; will require a constant internet connection for all game modes on consoles, <a href="https://www.benzinga.com/general/gaming/24/06/39257159/call-of-duty-black-ops-6-requires-constant-internet-connection-on-consoles-for-first-time" target="_blank" rel="noreferrer noopener">marking a first for the series</a>.
Related: <a target="_blank" href="https://www.benzinga.com/general/gaming/24/06/39277761/activision-confirms-call-of-duty-black-ops-6-wont-require-massive-300-gb-download" rel="noreferrer noopener">Activision Confirms Call Of Duty: Black Ops 6 Won&#8217;t Require Massive 300 GB Download</a>
Electronic Arts Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) EA Sports&nbsp;unveiled&nbsp;San Francisco 49ers running back&nbsp;Christian McCaffrey&nbsp;as <a target="_blank" href="https://www.benzinga.com/general/gaming/24/06/39280444/unveiling-madden-nfl-25-christian-mccaffreys-cover-debut-game-updates" rel="noreferrer noopener">the cover athlete for&nbsp;Madden NFL 25</a>.
Read: <a target="_blank" href="https://www.benzinga.com/general/gaming/24/06/39277698/resident-evil-village-hits-10m-sales-fastest-selling-game-in-series-history" rel="noreferrer noopener">Resident Evil Village Hits 10M Sales: Fastest-Selling Game In Series History</a>
Smartphones
Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) announced the first major update to visionOS at the WWDC 2024, bringing some important usability improvements to Apple Vision Pro users. Among these changes are memories, immersive <a href="https://www.benzinga.com/news/24/06/39256085/apples-vision-pro-to-debut-outside-us-markets-for-the-first-time-these-are-countries-on-tim-cooks-li" target="_blank" rel="noreferrer noopener">experiences and productivity improvements</a>.
Apple announced its new artificial intelligence&nbsp;initiative,&nbsp;Apple <a target="_blank" href="https://www.benzinga.com/news/24/06/39262940/apple-intelligence-to-be-limited-to-iphone-ipad-and-macs-and-wont-make-its-way-to-watch-tv-and-visio" rel="noreferrer noopener">Intelligence</a><a target="_blank" href="https://www.benzinga.com/news/24/06/39262940/apple-intelligence-to-be-limited-to-iphone-ipad-and-macs-and-wont-make-its-way-to-watch-tv-and-visio" rel="noreferrer noopener">, at the WWDC 2024</a>. Also, the company highlighted new features for iPads and iPhones and a deeper push to&nbsp;integrate <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39274000/7-apple-analysts-mixed-on-wwdc-2024-iphone-upgrade-cycle-coming-but-when" rel="noreferrer noopener">artificial intelligence on products</a>.
Related: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39285683/apple-analyst-says-you-dont-wanna-be-anywhere-near-the-stock-in-4-years-feels-wwdc-" rel="noreferrer noopener">Apple Analyst Says &#8216;You Don&#8217;t Wanna Be Anywhere Near The Stock&#8217; In 4 Years, Feels WWDC Was Like A &#8216;Snap CEO Talking Like We&#8217;re Gonna Target 22-Year Olds&#8217;</a>
Apple kicked off the iOS 18 update with some important quality-of-life improvements, including customization, smarter email organization, a <a href="https://www.benzinga.com/news/24/06/39256556/apple-unveils-ios-18-with-satellite-messaging-home-screen-customization-privacy-improvements-and-mor" target="_blank" rel="noreferrer noopener">better messaging experience and more</a>.
Apple revealed that it is partnering with Microsoft-backed OpenAI to integrate ChatGPT into iOS 18, <a href="https://www.benzinga.com/news/24/06/39258186/apple-integrates-new-chatgpt-features-in-iphone-mac-and-ipad-sam-altman-thinks-you-will-really-like" target="_blank" rel="noreferrer noopener">iPadOS 18 and macOS 15 Sequoia</a>.
Related: <a target="_blank" href="https://www.benzinga.com/news/24/06/39284760/tesla-ex-ai-chief-andrej-karpathy-really-liked-wwdc-2024-announcements-but-grok-investor-pierre-ferr" rel="noreferrer noopener">Tesla Ex-AI Chief Andrej Karpathy &#8216;Really Liked&#8217; WWDC 2024 Announcements But Grok-Investor Pierre Ferragu Skeptical On Execution: &#8216;Can Apple Make It Work?&#8217;</a>
Apple&#8217;s Tim Cook&nbsp;has expressed uncertainty about the company&#8217;s ability to completely&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/06/39285737/tim-cook-admits-he-has-doubts-about-apples-ability-to-prevent-ai-hallucinations-i-would-never-claim" rel="noreferrer noopener">prevent AI hallucinations</a>.
CEO&nbsp;Tim Cook&nbsp;said that the company&#8217;s objective is not to increase device usage but to enable users to achieve things they couldn&#8217;t without their devices, after&nbsp;unveiling <a target="_blank" href="https://www.benzinga.com/news/24/06/39305868/tim-cook-aims-to-help-apple-users-accomplish-more-without-extending-screen-time-we-want-to-empower-y" rel="noreferrer noopener">Apple Intelligence&nbsp;earlier this week</a>.
Apple has revealed its plans to integrate&nbsp;Alphabet Inc.&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)&nbsp;Google Gemini&nbsp;AI model into its&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/06/39271592/apple-may-introduce-google-gemini-ai-model-for-iphone-mac-and-ipad-says-craig-federighi" rel="noreferrer noopener">Apple Intelligence feature set</a>.
Apple has rejected the submission of UTM, a generic PC system emulator, from the iOS App Store and&nbsp;third-party app stores, despite the European Union&#8217;s recent efforts to loosen its <a target="_blank" href="https://www.benzinga.com/news/24/06/39250102/apple-blocks-emulator-app-for-iphones-from-app-store-and-alternative-stores-showing-it-still-exerts" rel="noreferrer noopener">control using the Digital Markets Act, or DMA</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/06/39244134/ming-chi-kuo-says-iphone-16-shipments-to-fall-5-yoy-ios18s-unveiling-at-apples-wwdc-2024-will-have-l" rel="noreferrer noopener">Ming-Chi Kuo Says iPhone 16 Shipments To Fall 5% YoY: iOS18&#8217;s Unveiling At Apple&#8217;s WWDC 2024 Will Have Limited Impact On Replacement Demand</a>
Tech
The Turkish Competition Board has fined Google approximately $14.85 million (482 million Turkish Lira) for non-compliance <a href="https://www.benzinga.com/news/24/06/39250744/google-hit-with-14-85m-fine-by-turkish-authority-over-local-search-compliance" target="_blank" rel="noreferrer noopener">with local competition regulations</a>.
Alphabet has been hit with a privacy complaint by Austrian advocacy group NOYB. The complaint alleges that Google tracks users of its <a target="_blank" href="https://www.benzinga.com/news/24/06/39305523/another-setback-for-google-alphabet-faces-austrian-privacy-complaint-over-chrome-tracking" rel="noreferrer noopener">Chrome browser without proper consent</a>.
The new head of search of Google, Liz Reid, has conveyed that the company will not always be able to detect errors in AI searches. This statement was made <a href="https://www.benzinga.com/news/24/06/39313168/google-search-chief-tells-employees-dont-hold-back-features-just-because-there-might-be-occasional-p" target="_blank" rel="noreferrer noopener">at a recent all-hands meeting</a>. 
Dexcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), a&nbsp;leading glucose monitor manufacturer, has enabled&nbsp;direct&nbsp;Apple&#8217;s AAPL&nbsp;Watch connectivity for&nbsp;its&nbsp;G7 model <a href="https://www.benzinga.com/news/24/06/39244233/apple-watch-now-directly-syncs-with-dexcoms-g7-glucose-monitor" target="_blank" rel="noreferrer noopener">in the&nbsp;United States</a>.
Samsung Electronics Co. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SSNLF#OTC">SSNLF</a>)&nbsp;has reportedly combined its two North American AI research centers and appointed a former&nbsp;Apple Inc.&nbsp;AAPL&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/06/39284417/ex-apple-siri-guru-to-lead-samsungs-north-american-ai-division" rel="noreferrer noopener">executive to head the newly formed division</a>.
The chairman of Samsung Electronics, Jay Y. Lee, has been in discussions with the heads of Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Amazon.com and Qualcomm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>). The discussions revolved around potential areas of cooperation, including artificial intelligence, <a href="https://www.benzinga.com/news/24/06/39310074/samsung-chairman-engages-in-strategic-talks-with-meta-amazon-and-qualcomm" target="_blank" rel="noreferrer noopener">cloud services and semiconductors</a>.
Meta Platforms has been hit with a complaint in Norway for using user images and posts from <a href="https://www.benzinga.com/news/24/06/39307741/meta-platforms-under-fire-in-norway-for-using-private-user-data-from-facebook-instagram-for-ai-train" target="_blank" rel="noreferrer noopener">Facebook and Instagram to train AI models</a>.
Elon Musk
Tesla Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and&nbsp;SpaceX&nbsp;CEO&nbsp;Elon Musk&nbsp;on Sunday put an end to the&nbsp;speculation <a target="_blank" href="https://www.benzinga.com/news/24/06/39244688/elon-musk-shuts-down-smartphone-rumors-we-are-not-going-to-do-a-tesla-phone" rel="noreferrer noopener">about a potential&nbsp;Tesla smartphone</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/06/39246781/elon-musk-thinks-humanoid-robots-will-one-day-exceed-human-population-from-nvidias-project-gr00t-to" rel="noreferrer noopener">Elon Musk Thinks Humanoid Robots Will One Day Exceed Human Population: From Nvidia&#8217;s Project GR00T To Tesla&#8217;s Optimus, Here Are Top 7 Projects Currently Underway</a>
Presumptive Republican candidate&nbsp;Donald Trump&#8217;s&nbsp;niece&nbsp;Mary Trump&nbsp;<a target="_blank" href="https://www.benzinga.com/news/23/09/34306743/trumps-niece-slams-elon-musk-for-his-anti-woke-comments-blames-him-for-destroying-twitter" rel="noreferrer noopener">has once again criticized</a>&nbsp;Tesla and&nbsp;SpaceX CEO&nbsp;Elon Musk for allegedly destroying&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/06/39303823/trumps-niece-slams-latest-improvement-to-x-elon-musk-is-even-stupider-than-i-thought" rel="noreferrer noopener">Twitter</a><a target="_blank" href="https://www.benzinga.com/news/24/06/39303823/trumps-niece-slams-latest-improvement-to-x-elon-musk-is-even-stupider-than-i-thought" rel="noreferrer noopener">, now rebranded as&nbsp;</a><a target="_blank" href="https://www.benzinga.com/news/24/06/39303823/trumps-niece-slams-latest-improvement-to-x-elon-musk-is-even-stupider-than-i-thought" rel="noreferrer noopener">X</a>.
Musk&#8217;s&nbsp;X, formerly&nbsp;Twitter, is set to roll out a new feature that will allow users to&nbsp;keep their likes private. This move is aimed at protecting users from <a target="_blank" href="https://www.benzinga.com/news/24/06/39284004/elon-musk-introduces-private-likes-to-protect-users-but-people-want-to-know-about-the-rampant-adult" rel="noreferrer noopener">potential backlash for their online activity</a>.
Read: <a target="_blank" href="https://www.benzinga.com/news/24/06/39264633/as-elon-musk-blasts-apples-partnership-with-chatgpt-parent-openai-analysts-say-theres-definitely-an" rel="noreferrer noopener">As Elon Musk Blasts Apple&#8217;s Partnership With ChatGPT-Parent OpenAI, Analysts Say There&#8217;s Definitely &#8216;An Unanswered Question&#8217;</a>
Artificial Intelligence (AI)
Elon Musk withdrew his lawsuit against OpenAI and its co-founders, Sam Altman and Greg Brockman. His decision came a day after he went on a tirade and criticized Apple <a href="https://www.benzinga.com/news/24/06/39283661/elon-musk-drops-openai-lawsuit-involving-sam-altman-greg-brockman-a-day-after-blasting-apple-for-par" target="_blank" rel="noreferrer noopener">for partnering with the </a><a href="https://www.benzinga.com/news/24/06/39283661/elon-musk-drops-openai-lawsuit-involving-sam-altman-greg-brockman-a-day-after-blasting-apple-for-par" target="_blank" rel="noreferrer noopener">ChatGPT</a><a href="https://www.benzinga.com/news/24/06/39283661/elon-musk-drops-openai-lawsuit-involving-sam-altman-greg-brockman-a-day-after-blasting-apple-for-par" target="_blank" rel="noreferrer noopener"> parent</a>.
Read: <a target="_blank" href="https://www.benzinga.com/news/24/06/39304829/ai-is-helping-cat-owners-in-tokyo-keep-their-feline-friends-healthier-app-can-reportedly-detect-pain" rel="noreferrer noopener">AI Is Helping Cat Owners In Tokyo Keep Their Feline Friends Healthier: App Can Reportedly Detect Pain With More Than 95% Accuracy</a>
Apple&#8217;s Craig Federighi&nbsp;has revealed that users will be able to opt&nbsp;out of the integration&nbsp;of&nbsp;OpenAI&#8217;s ChatGPT, a move that could alleviate <a target="_blank" href="https://www.benzinga.com/news/24/06/39287140/elon-musk-reacts-as-apple-offers-opt-out-option-for-openais-chatgpt-integration-easing-privacy-conce" rel="noreferrer noopener">mounting concerns about AI privacy</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/06/39284426/google-engineer-says-sam-altman-led-openai-set-back-ai-research-progress-by-5-10-years-llms-have-suc" rel="noreferrer noopener">Google Engineer Says Sam Altman-Led OpenAI Set Back AI Research Progress By 5-10 Years: &#8216;LLMs Have Sucked The Oxygen Out Of The Room&#8217;</a>
OpenAI&#8217;s Mira Murati&nbsp;responded to&nbsp;Elon Musk&#8217;s&nbsp;criticism of the&nbsp;company&#8217;s partnership&nbsp;with&nbsp;Apple&#8217;s emphasizing OpenAI&#8217;s <a target="_blank" href="https://www.benzinga.com/news/24/06/39290929/key-openai-executive-defends-apple-partnership-against-elon-musks-creepy-spyware-accusation-we-care" rel="noreferrer noopener">commitment to user privacy</a>.
Related: <a href="https://www.benzinga.com/news/24/06/39291654/craig-federighi-explains-how-apple-intelligence-maintains-user-privacy-amid-concerns-over-chatgpt-in" target="_blank" rel="noreferrer noopener">Craig Federighi Explains How Apple Intelligence Maintains User Privacy Amid Concerns Over ChatGPT Integration</a>
Photo: Shutterstock

What's New In the Consumer Tech World Last Week? News That You Should Know (June 9-June 15, 2024)

DexCom's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NYSE">DXCM</a>) short percent of float has fallen 29.84% since its last report. The company recently reported that it has 7.78 million shares sold short, which is 2.21% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.98 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>DexCom Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1718128818_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for DexCom has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing DexCom's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, DexCom's peer group average for short interest as a percentage of float is 4.76%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Peering Into DexCom's Recent Short Interest

Dexcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), a <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37034413/continuous-glucose-monitor-maker-dexcoms-q4-profit-triples-on-volume-growth-and-new">leading glucose monitor manufacturer</a>, has enabled direct Apple Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) Watch connectivity for its G7 model in the United States.
What Happened:&nbsp;The new <a href="https://www.benzinga.com/markets/equities/23/07/33112307/dexcom-g7-continuous-glucose-monitoring-system-gets-regulatory-nod-from-health-canada">feature allows G7 users</a> to access real-time&nbsp;glucose data on their Apple&nbsp;Watch through Dexcom&#8217;s new app, without needing to sync with an iPhone. 
Bloomberg columnist Mark Gurman revealed the information in his latest installment of the weekly &#8220;Power On&#8221; newsletter. This update is particularly beneficial&nbsp;for Apple Watch users who&nbsp;prefer to leave their phones behind occasionally.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
As of 2022, approximately&nbsp;24.4 million people in the&nbsp;U.S. were&nbsp;diagnosed with diabetes, according to&nbsp;Statista. Globally, the number of diabetics was 537 million in 2021, a figure expected to rise to 783 million by 2045.
Why It Matters: The glucose monitoring market is significant, with millions of people worldwide needing to constantly check their blood sugar levels. Dexcom&#8217;s system still necessitates a skin prick, <a href="https://www.benzinga.com/news/24/01/36729565/samsung-to-reportedly-level-up-its-health-tech-game-plans-to-challenge-apple-with-noninvasive-blood">but tech giants like</a>&nbsp;Apple and&nbsp;Samsung Electronics Co.&nbsp;are working on <a href="https://www.benzinga.com/news/23/02/31013567/what-does-apple-have-to-do-with-dexcom-stock-trading-lower">developing monitors that eliminate</a> the need for blood draw.
In February earlier this year, the Food and Drug Administration cautioned&nbsp;against the use of smartwatches or smart rings claiming to measure blood glucose levels without skin penetration, stating that <a href="https://www.benzinga.com/news/large-cap/24/02/37260313/do-not-use-smartwatches-rings-that-claim-to-measure-blood-sugar-without-needles-fda-says">no such device has been approved yet</a>.
&#8220;The agency is working to ensure that manufacturers, distributors, and sellers do not illegally market unauthorized smartwatches or smart rings that claim to measure blood glucose levels,&#8221; the FDA said in the statement.
Meanwhile, Dexcom has been <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37522301/fda-approval-for-dexcoms-stelo-opens-continuous-glucose-monitoring-to-masses-analys">expanding its product line</a>. In March 2024, the FDA approved Dexcom&#8217;s Stelo Glucose Biosensor System, the first over-the-counter continuous glucose monitor. It is an integrated continuous glucose monitor designed for individuals 18 years and older who do not use insulin.
Photo by Anna Hoychuk on Shutterstock
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:&nbsp;<a href="https://www.benzinga.com/news/24/06/39175566/jeff-bezos-once-picked-up-the-phone-and-called-amazon-customer-support-to-make-a-point-and-set-off-w?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Jeff Bezos Once Picked Up The Phone And Called Amazon Customer Support To Make A Point And Set Off ‘Whole Chain Of Events': Here's Why</a>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Apple Watch Now Directly Syncs With Dexcom's G7 Glucose Monitor

DexCom Announced Today That The Dexcom G7 Continuous Glucose Monitoring System Now Connects Directly To Apple Watch In The United States

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CERE</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/19/24</td>
<td>$40.00</td>
<td>$56.0K</td>
<td>3</td>
<td>2.9K</td>
</tr>
<tr>
<td>LFMD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$7.50</td>
<td>$54.4K</td>
<td>2.3K</td>
<td>836</td>
</tr>
<tr>
<td>INCY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$60.00</td>
<td>$57.5K</td>
<td>6.3K</td>
<td>664</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$110.00</td>
<td>$43.0K</td>
<td>3.0K</td>
<td>362</td>
</tr>
<tr>
<td>NVAX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$30.00</td>
<td>$378.0K</td>
<td>308</td>
<td>303</td>
</tr>
<tr>
<td>EXAS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$47.50</td>
<td>$29.4K</td>
<td>1.5K</td>
<td>181</td>
</tr>
<tr>
<td>BMRN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$75.00</td>
<td>$32.3K</td>
<td>525</td>
<td>68</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$115.00</td>
<td>$33.9K</td>
<td>20</td>
<td>32</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$30.00</td>
<td>$66.0K</td>
<td>1.2K</td>
<td>26</td>
</tr>
<tr>
<td>BSX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$60.00</td>
<td>$31.9K</td>
<td>2.8K</td>
<td>20</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding CERE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERE#NASDAQ">CERE</a>), we observe a put option trade with neutral sentiment. It expires in 45 day(s) on July 19, 2024. Parties traded 400 contract(s) at a $40.00 strike. The total cost received by the writing party (or parties) was $56.0K, with a price of $140.0 per contract. There were 3 open contracts at this strike prior to today, and today 2910 contract(s) were bought and sold. 
• For LFMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFMD#NASDAQ">LFMD</a>), we notice a call option sweep that happens to be bullish, expiring in 164 day(s) on November 15, 2024. This event was a transfer of 389 contract(s) at a $7.50 strike. This particular call needed to be split into 13 different trades to become filled. The total cost received by the writing party (or parties) was $54.4K, with a price of $140.0 per contract. There were 2327 open contracts at this strike prior to today, and today 836 contract(s) were bought and sold. 
• For INCY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>), we notice a call option trade that happens to be bearish, expiring in 17 day(s) on June 21, 2024. This event was a transfer of 500 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $57.5K, with a price of $115.0 per contract. There were 6331 open contracts at this strike prior to today, and today 664 contract(s) were bought and sold. 
• For ABT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), we notice a call option sweep that happens to be bullish, expiring in 73 day(s) on August 16, 2024. This event was a transfer of 336 contract(s) at a $110.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $43.0K, with a price of $128.0 per contract. There were 3029 open contracts at this strike prior to today, and today 362 contract(s) were bought and sold. 
• For NVAX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>), we notice a put option trade that happens to be bullish, expiring in 45 day(s) on July 19, 2024. This event was a transfer of 300 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $378.0K, with a price of $1260.0 per contract. There were 308 open contracts at this strike prior to today, and today 303 contract(s) were bought and sold. 
• For EXAS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), we notice a put option sweep that happens to be bullish, expiring in 17 day(s) on June 21, 2024. This event was a transfer of 67 contract(s) at a $47.50 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $29.4K, with a price of $440.0 per contract. There were 1546 open contracts at this strike prior to today, and today 181 contract(s) were bought and sold. 
• Regarding BMRN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>), we observe a put option trade with bearish sentiment. It expires in 227 day(s) on January 17, 2025. Parties traded 66 contract(s) at a $75.00 strike. The total cost received by the writing party (or parties) was $32.3K, with a price of $490.0 per contract. There were 525 open contracts at this strike prior to today, and today 68 contract(s) were bought and sold. 
• For DXCM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), we notice a put option trade that happens to be bullish, expiring in 199 day(s) on December 20, 2024. This event was a transfer of 32 contract(s) at a $115.00 strike. The total cost received by the writing party (or parties) was $33.9K, with a price of $1060.0 per contract. There were 20 open contracts at this strike prior to today, and today 32 contract(s) were bought and sold. 
• Regarding VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we observe a call option sweep with bullish sentiment. It expires in 227 day(s) on January 17, 2025. Parties traded 22 contract(s) at a $30.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $66.0K, with a price of $3000.0 per contract. There were 1261 open contracts at this strike prior to today, and today 26 contract(s) were bought and sold. 
• Regarding BSX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), we observe a call option sweep with bullish sentiment. It expires in 17 day(s) on June 21, 2024. Parties traded 20 contract(s) at a $60.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $31.9K, with a price of $1599.0 per contract. There were 2846 open contracts at this strike prior to today, and today 20 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

BMRN

CERE

EXAS

INCY

LFMD

NVAX

VKTX

10 Health Care Stocks Whale Activity In Today's Session

Biotech

Dexcom Secures Access To Dexcom ONE Sensor For 100,000 Type 2 Diabetes Patients In France; French Government Offers Full National Reimbursement For CGM Technology

DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) has outperformed the market over the past 5 years by 16.83% on an annualized basis producing an average annual return of 29.54%. Currently, DexCom has a market capitalization of $45.69 billion. 
Buying $1000 In DXCM: If an investor had bought $1000 of DXCM stock 5 years ago, it would be worth $3,807.28 today based on a price of $114.88 for DXCM at the time of writing.
<h3>DexCom's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1717435830_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,800 Today

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRAX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$45.00</td>
<td>$37.5K</td>
<td>1.2K</td>
<td style="text-align: right;">492</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$130.00</td>
<td>$27.1K</td>
<td>3.0K</td>
<td style="text-align: right;">349</td>
</tr>
<tr>
<td>EXEL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$18.00</td>
<td>$75.0K</td>
<td>0</td>
<td style="text-align: right;">300</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$260.00</td>
<td>$787.5K</td>
<td>10</td>
<td style="text-align: right;">300</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$47.00</td>
<td>$42.8K</td>
<td>3.0K</td>
<td style="text-align: right;">211</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$530.00</td>
<td>$66.6K</td>
<td>786</td>
<td style="text-align: right;">161</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$110.00</td>
<td>$92.7K</td>
<td>346</td>
<td style="text-align: right;">141</td>
</tr>
<tr>
<td>SRPT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$160.00</td>
<td>$46.4K</td>
<td>1.0K</td>
<td style="text-align: right;">117</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$180.00</td>
<td>$89.1K</td>
<td>533</td>
<td style="text-align: right;">6</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$67.50</td>
<td>$27.4K</td>
<td>311</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For PRAX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>), we notice a put option trade that happens to be bullish, expiring in 49 day(s) on July 19, 2024. This event was a transfer of 50 contract(s) at a $45.00 strike. The total cost received by the writing party (or parties) was $37.5K, with a price of $750.0 per contract. There were 1208 open contracts at this strike prior to today, and today 492 contract(s) were bought and sold. 
• For MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we notice a put option trade that happens to be bullish, expiring in 21 day(s) on June 21, 2024. This event was a transfer of 100 contract(s) at a $130.00 strike. The total cost received by the writing party (or parties) was $27.1K, with a price of $271.0 per contract. There were 3017 open contracts at this strike prior to today, and today 349 contract(s) were bought and sold. 
• For EXEL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>), we notice a call option trade that happens to be bearish, expiring in 168 day(s) on November 15, 2024. This event was a transfer of 150 contract(s) at a $18.00 strike. The total cost received by the writing party (or parties) was $75.0K, with a price of $500.0 per contract. There were 0 open contracts at this strike prior to today, and today 300 contract(s) were bought and sold. 
• Regarding DHR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), we observe a put option trade with bullish sentiment. It expires in 595 day(s) on January 16, 2026. Parties traded 300 contract(s) at a $260.00 strike. The total cost received by the writing party (or parties) was $787.5K, with a price of $2625.0 per contract. There were 10 open contracts at this strike prior to today, and today 300 contract(s) were bought and sold. 
• Regarding BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we observe a put option trade with bullish sentiment. It expires in 112 day(s) on September 20, 2024. Parties traded 64 contract(s) at a $47.00 strike. The total cost received by the writing party (or parties) was $42.8K, with a price of $670.0 per contract. There were 3098 open contracts at this strike prior to today, and today 211 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a call option trade that happens to be bullish, expiring in 49 day(s) on July 19, 2024. This event was a transfer of 112 contract(s) at a $530.00 strike. The total cost received by the writing party (or parties) was $66.6K, with a price of $595.0 per contract. There were 786 open contracts at this strike prior to today, and today 161 contract(s) were bought and sold. 
• For DXCM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), we notice a put option sweep that happens to be bearish, expiring in 168 day(s) on November 15, 2024. This event was a transfer of 127 contract(s) at a $110.00 strike. This particular put needed to be split into 32 different trades to become filled. The total cost received by the writing party (or parties) was $92.7K, with a price of $730.0 per contract. There were 346 open contracts at this strike prior to today, and today 141 contract(s) were bought and sold. 
• Regarding SRPT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), we observe a call option sweep with bearish sentiment. It expires in 21 day(s) on June 21, 2024. Parties traded 91 contract(s) at a $160.00 strike. This particular call needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $46.4K, with a price of $510.0 per contract. There were 1044 open contracts at this strike prior to today, and today 117 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a call option sweep that happens to be bearish, expiring in 385 day(s) on June 20, 2025. This event was a transfer of 151 contract(s) at a $180.00 strike. This particular call needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $89.1K, with a price of $590.0 per contract. There were 533 open contracts at this strike prior to today, and today 6 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a call option sweep with bullish sentiment. It expires in 595 day(s) on January 16, 2026. Parties traded 50 contract(s) at a $67.50 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $27.4K, with a price of $550.0 per contract. There were 311 open contracts at this strike prior to today, and today 0 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABBV

EXEL

MRNA

PRAX

SRPT

DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $154.0, along with a high estimate of $165.00 and a low estimate of $130.00. This current average has increased by 3.36% from the previous average price target of $149.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1717074060_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive DexCom. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Issie Kirby</td>
<td>Redburn Atlantic</td>
<td>Announces</td>
<td>Neutral</td>
<td>$130.00</td>
<td>-</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$160.00</td>
<td>$151.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$145.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$163.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$161.00</td>
<td>$148.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$165.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to DexCom. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of DexCom compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of DexCom's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of DexCom's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DXCM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on DexCom analyst ratings.</a>
<h2>Discovering DexCom: A Closer Look</h2>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
<h3>Key Indicators: DexCom's Financial Health</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Positive Revenue Trend: Examining DexCom's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 24.21% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 15.9%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): DexCom's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.78% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): DexCom's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.3% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: DexCom's debt-to-equity ratio surpasses industry norms, standing at 1.15. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

In-Depth Examination Of 6 Analyst Recommendations For DexCom

Redburn Atlantic analyst Issie Kirby initiates coverage on DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Neutral rating and announces Price Target of $130.

Price Target

Redburn Atlantic Initiates Coverage On DexCom with Neutral Rating, Announces Price Target of $130

DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) has outperformed the market over the past 5 years by 20.72% on an annualized basis producing an average annual return of 33.47%. Currently, DexCom has a market capitalization of $50.53 billion. 
Buying $100 In DXCM: If an investor had bought $100 of DXCM stock 5 years ago, it would be worth $418.74 today based on a price of $127.05 for DXCM at the time of writing.
<h3>DexCom's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715628613_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 5 Years Ago Would Be Worth $400 Today

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$47.00</td>
<td>$54.8K</td>
<td>1.6K</td>
<td>1.7K</td>
</tr>
<tr>
<td>ARDX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/03/24</td>
<td>$7.50</td>
<td>$37.5K</td>
<td>921</td>
<td>435</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$320.00</td>
<td>$48.3K</td>
<td>20</td>
<td>250</td>
</tr>
<tr>
<td>BDX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$235.00</td>
<td>$111.2K</td>
<td>1.1K</td>
<td>207</td>
</tr>
<tr>
<td>HROW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$6.00</td>
<td>$49.2K</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>CI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$350.00</td>
<td>$49.9K</td>
<td>111</td>
<td>76</td>
</tr>
<tr>
<td>MDGL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$260.00</td>
<td>$61.5K</td>
<td>62</td>
<td>50</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$120.00</td>
<td>$41.2K</td>
<td>0</td>
<td>43</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$650.00</td>
<td>$46.0K</td>
<td>131</td>
<td>42</td>
</tr>
<tr>
<td>TMDX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$100.00</td>
<td>$31.8K</td>
<td>115</td>
<td>26</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we observe a call option sweep with bearish sentiment. It expires in 49 day(s) on June 21, 2024. Parties traded 1276 contract(s) at a $47.00 strike. This particular call needed to be split into 26 different trades to become filled. The total cost received by the writing party (or parties) was $54.8K, with a price of $43.0 per contract. There were 1632 open contracts at this strike prior to today, and today 1797 contract(s) were bought and sold. 
• For ARDX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>), we notice a call option trade that happens to be bullish, is expiring today. Parties traded 250 contract(s) at a $7.50 strike. The total cost received by the writing party (or parties) was $37.5K, with a price of $150.0 per contract. There were 921 open contracts at this strike prior to today, and today 435 contract(s) were bought and sold. 
• For AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we notice a put option sweep that happens to be bullish, expiring in 105 day(s) on August 16, 2024. This event was a transfer of 24 contract(s) at a $320.00 strike. This particular put needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $48.3K, with a price of $2015.0 per contract. There were 20 open contracts at this strike prior to today, and today 250 contract(s) were bought and sold. 
• Regarding BDX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>), we observe a call option sweep with bearish sentiment. It expires in 14 day(s) on May 17, 2024. Parties traded 206 contract(s) at a $235.00 strike. This particular call needed to be split into 26 different trades to become filled. The total cost received by the writing party (or parties) was $111.2K, with a price of $540.0 per contract. There were 1190 open contracts at this strike prior to today, and today 207 contract(s) were bought and sold. 
• Regarding HROW (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>), we observe a call option trade with bullish sentiment. It expires in 168 day(s) on October 18, 2024. Parties traded 100 contract(s) at a $6.00 strike. The total cost received by the writing party (or parties) was $49.2K, with a price of $492.0 per contract. There were 0 open contracts at this strike prior to today, and today 100 contract(s) were bought and sold. 
• For CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we notice a call option sweep that happens to be bearish, expiring in 196 day(s) on November 15, 2024. This event was a transfer of 21 contract(s) at a $350.00 strike. This particular call needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $49.9K, with a price of $2380.0 per contract. There were 111 open contracts at this strike prior to today, and today 76 contract(s) were bought and sold. 
• Regarding MDGL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>), we observe a call option trade with bullish sentiment. It expires in 77 day(s) on July 19, 2024. Parties traded 50 contract(s) at a $260.00 strike. The total cost received by the writing party (or parties) was $61.5K, with a price of $1230.0 per contract. There were 62 open contracts at this strike prior to today, and today 50 contract(s) were bought and sold. 
• Regarding DXCM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), we observe a put option trade with bullish sentiment. It expires in 231 day(s) on December 20, 2024. Parties traded 43 contract(s) at a $120.00 strike. The total cost received by the writing party (or parties) was $41.2K, with a price of $960.0 per contract. There were 0 open contracts at this strike prior to today, and today 43 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option trade with bearish sentiment. It expires in 14 day(s) on May 17, 2024. Parties traded 5 contract(s) at a $650.00 strike. The total cost received by the writing party (or parties) was $46.0K, with a price of $9200.0 per contract. There were 131 open contracts at this strike prior to today, and today 42 contract(s) were bought and sold. 
• Regarding TMDX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>), we observe a call option trade with bearish sentiment. It expires in 77 day(s) on July 19, 2024. Parties traded 10 contract(s) at a $100.00 strike. The total cost received by the writing party (or parties) was $31.8K, with a price of $3180.0 per contract. There were 115 open contracts at this strike prior to today, and today 26 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMGN

ARDX

HROW

MDGL

TMDX

DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) has outperformed the market over the past 15 years by 25.99% on an annualized basis producing an average annual return of 38.03%. Currently, DexCom has a market capitalization of $50.89 billion. 
Buying $1000 In DXCM: If an investor had bought $1000 of DXCM stock 15 years ago, it would be worth $127,970.00 today based on a price of $127.97 for DXCM at the time of writing.
<h3>DexCom's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714494626_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In DexCom 15 Years Ago Would Be Worth Today

Shares of Aon plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) fell sharply during Friday's session after the company reported worse-than-expected <a href="https://www.benzinga.com/quote/AON/earnings">quarterly financial results</a>.
Aon posted adjusted earnings of $5.66 per share, missing market estimates of $5.91 per share. The company's sales came in at $4.070 billion versus expectations of $4.126 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Aon shares dipped 7.4% to $283.19 on Friday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Biodexa Pharmaceuticals Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares jumped 73.3% to $1.2475 after the company entered an exclusive license agreement with Rapamycin Holdings for the rights to eRapa.</li>
<li>Pineapple Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) gained 63% to $0.0845.</li>
<li>NewGenIvf Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares gained 55% to $2.01 after dipping 16% on Thursday.</li>
<li>Universal Logistics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULH#NASDAQ">ULH</a>) surged 45.2% to $47.76 after the company reported better-than-expected first-quarter financial results.</li>
<li>Focus Universal Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCUV#NASDAQ">FCUV</a>) jumped 40% to $0.3967 after the company announced board approval for the spin-off of Lusher.</li>
<li>BranchOut Food Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOF#NASDAQ">BOF</a>) gained 37% to $2.68.</li>
<li>Concord Medical Services Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCM#NYSE">CCM</a>) gained 29% to $0.6502. Concord Medical filed 2023 annual report on Form 20-F.</li>
<li>Exponent, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPO#NASDAQ">EXPO</a>) shares climbed 28.5% to $102.41 after the company reported better-than-expected first-quarter financial results.</li>
<li>Skillsoft Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKIL#NYSE">SKIL</a>) climbed 26.4% to $8.60.</li>
<li>MultiMetaVerse Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMV#NASDAQ">MMV</a>) gained 24.2% to $0.61.</li>
<li>Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) gained 23% to $14.02 after the company reported better-than-expected first-quarter financial results and issued second-quarter revenue guidance above estimates. Also, the company reported a year-over-year increase in quarterly daily active users.</li>
<li>Tutor Perini Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPC#NYSE">TPC</a>) surged 22.2% to $16.98 after the company reported better-than-expected first-quarter financial results and issued FY24 EPS guidance.</li>
<li>Sunshine Biopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) surged 22.2% to $0.9888.</li>
<li>U.S. Silica Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLCA#NYSE">SLCA</a>) gained 20% to $15.67 after the company reported first-quarter financial results and entered into a definitive agreement to be acquired by funds managed by affiliates of Apollo.</li>
<li>Earlyworks Co., Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELWS#NASDAQ">ELWS</a>) rose 19.7% to $0.8725 after gaining 19% on Thursday.</li>
<li>Cullinan Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEM#NASDAQ">CGEM</a>) surged 19.5% to $23.03.</li>
<li>Tevogen Bio Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares gained 19.3% to $1.0150 after falling over 43% on Thursday.</li>
<li>ATRenew Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RERE#NASDAQ">RERE</a>) surged 18.9% to $1.9150. ATRenew announced appointment of new director.</li>
<li>ZIM Integrated Shipping Services Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) gained 17.5% to $13.39.</li>
<li>Freight Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRGT#NASDAQ">FRGT</a>) climbed 17% to $1.0702 after gaining 5% on Thursday.</li>
<li>Skechers U.S.A., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>) shares gained 16% to $68.20 after the company reported better-than-expected first-quarter FY24 earnings.</li>
<li>AppFolio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPF#NASDAQ">APPF</a>) surged 16% to $251.22 after the company reported better-than-expected first-quarter financial results and raised its FY24 revenue guidance above estimates.</li>
<li>Newell Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>) gained 15% to $7.97 after the company reported better than expected first-quarter earnings and issued guidance.</li>
<li>ResMed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) shares rose 13.7% to $208.63 after the company reported better-than-expected third-quarter financial results.</li>
<li>Rogers Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROG#NYSE">ROG</a>) surged 12.7% to $123.46 after the company beat first-quarter EPS and sales estimates.</li>
<li>iLearningEngines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AILE#NASDAQ">AILE</a>) gained 11.3% to $7.92</li>
<li>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) rose 10.6% to $172.52 the company posted upbeat results for its first quarter. Alphabet's board authorized an additional share repurchase program of up to $70 billion and also announced its first-ever quarterly dividend.</li>
<li>Kratos Defense &amp; Security Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTOS#NASDAQ">KTOS</a>) gained 8.8% to $18.80 after Raymond James upgraded the stock from Outperform to Strong Buy and raised its price target from $20 to $27.</li>
<li>AutoNation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AN#NYSE">AN</a>) climbed 8.6% to $174.20 following second-quarter results.</li>
<li>Kintara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) shares gained 8.4% to $0.8725 after gaining 15% on Thursday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>iClick Interactive Asia Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLK#NASDAQ">ICLK</a>) shares fell 48.8% to $1.31 after the company announced the termination of its merger agreement.</li>
<li>Nuwellis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) fell 46.7% to $0.1540 after the company reported pricing of $2.7 million public offering.</li>
<li>Safe &amp; Green Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGBX#NASDAQ">SGBX</a>) fell 27.7% to $0.1584.</li>
<li>E-Home Household Service Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EJH#NASDAQ">EJH</a>) dipped 25.3% to $0.5752.</li>
<li>Nature Wood Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWGL#NASDAQ">NWGL</a>) fell 24.5% to $12.71.</li>
<li>IMAC Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BACK#NASDAQ">BACK</a>) dipped 22.9% to $3.93.</li>
<li>reAlpha Tech Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRE#NASDAQ">AIRE</a>) fell 20.8% to $1.10.</li>
<li>ZyVersa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) fell 19.3% to $4.84.</li>
<li>Saia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) dipped 19.1% to $439.40 after the company reported worse-than-expected first-quarter financial results.</li>
<li>Kinsale Capital Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNSL#NYSE">KNSL</a>) fell 17.3% to $374.29 following first-quarter results.</li>
<li>Aclarion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) fell 15.5% to $0.3319. Aclarion shares jumped 36% on Thursday after the company announced that its Nociscan solution will be used in the upcoming LIFEHAB trial evaluating the diagnosis and treatment of chronic low back pain.</li>
<li>Oil States International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OIS#NYSE">OIS</a>) fell 15% to $4.5250 after the company reported worse-than-expected first-quarter financial results.</li>
<li>Boyd Gaming Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>) shares declined 14.8% to $53.55 after the company reported worse-than-expected first-quarter adjusted EPS results.</li>
<li>Avenue Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXI#NASDAQ">ATXI</a>) fell 13.5% to $7.59.</li>
<li>Chicken Soup for the Soul Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSSE#NASDAQ">CSSE</a>) fell 12.7% to $0.2260 after dipping 39% on Thursday. Chicken Soup For The Soul Entertainment received delinquency letter from the Nasdaq.</li>
<li>TriNet Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNET#NYSE">TNET</a>) fell 11.5% to $112.11 after the company reported worse-than-expected first-quarter results and issued weak guidance.</li>
<li>Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) shares fell 11.1% to $31.23 after the company reported worse-than-expected first-quarter sales results and issued EPS guidance below estimates.</li>
<li>Accolade, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACCD#NASDAQ">ACCD</a>) dipped 10.6% to $8.22 following quarterly results.</li>
<li>XPO, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>) fell 10.2% to $106.14.</li>
<li>Atlassian Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) shares fell 9.4% to $179.76 after the company reported third-quarter financial results. Atlassian said Scott Farquhar has decided to step down from his role as co-CEO, effective Aug. 31. Cannon-Brookes will continue to lead Atlassian as CEO.</li>
<li>Vincerx Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) shares fell 8.8% to $0.8180 after the company announced pricing of underwritten public offering of common stock and warrants.</li>
<li>SCWorx Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) fell 8.7% to $2.52 after surging 36% on Thursday.   </li>
<li>ACM Research, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACMR#NASDAQ">ACMR</a>) fell 8.3% to $25.94 after announcing preliminary unaudited revenue and shipments for the first quarter.</li>
<li>Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) shares fell 8.2% to $57.63 after the company reported first-quarter financial results.</li>
<li>Processa Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) fell 7.8% to $2.52. Processa Pharmaceuticals shares jumped 50% on Thursday after HC Wainwright &amp; Co initiated coverage on the stock with a Buy rating and announced an $8 price target.</li>
<li>Red Rock Resorts, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRR#NASDAQ">RRR</a>) dipped 7.4% to $54.83.</li>
<li>ArcBest Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCB#NASDAQ">ARCB</a>) declined 7.3% to $128.07.</li>
<li>Allison Transmission Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALSN#NYSE">ALSN</a>) fell 6.6% to $74.97 following first-quarter results.</li>
<li>Old Dominion Freight Line, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>) fell 6.2% to $184.41.</li>
<li>DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) shares declined 6.3% to $129.17 after the company reported first-quarter financial results.</li>
<li>Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) fell 4% to $116.44 following weak earnings.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/04/38459594/how-to-earn-500-a-month-from-dominos-pizza-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Domino&#8217;s Pizza Stock Ahead Of Q1 Earnings</a>

Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Raymond James analyst Jayson Bedford maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Strong Buy and raises the price target from $151 to $160.

Raymond James Maintains Strong Buy on DexCom, Raises Price Target to $160

Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Buy and raises the price target from $144 to $145.

Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $145

In a report released today, Josh Jennings from TD Cowen maintained a Buy rating on Dexcom (DXCM – Research Report). The company's shares closed las...

Dexcom (DXCM) Receives a Buy from TD Cowen

In a report released today, Travis Steed from Bank of America Securities maintained a Buy rating on Dexcom (DXCM – Research Report), with a price t...

Dexcom's Strategic Moves and Stelo Launch Justify Buy Rating

In a report released today, Matthew Taylor from Jefferies maintained a Buy rating on Dexcom (DXCM – Research Report), with a price target of $160.0...

Dexcom (DXCM) Gets a Buy from Jefferies

Tandem Diabetes, DexCom see weakness following ADA conference

In a report released on June 21, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Dexcom (DXCM – Research Report), with a price targ...

Dexcom (DXCM) Gets a Buy from RBC Capital

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
If you are looking for millionaire-maker stocks to turn a $50,000 portfolio into $1 million in just a decade, I&nbsp;would like&nbsp;to remind you of several things. First, your portfolio would need to compound at around 35% annually. Even if most stocks in your portfolio outperform the broader market&nbsp;going forward&nbsp;and meet expectations, this is very ambitious. Even Warren Buffett&rsquo;s returns have been around 20% since he started,&nbsp;and these returns&nbsp;have been more in line with the market in the past decade.



In addition, $50k is a&nbsp;pretty&nbsp;large&nbsp;sum for the average Joe.&nbsp;If you want to 20x that in a decade with no additional contributions&nbsp;along the way, the only stocks that could realistically do that are <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a>. I do not recommend putting this much money into penny stocks.



However, this&nbsp;doesn&rsquo;t mean&nbsp;that you&rsquo;re&nbsp;out of&nbsp;luck.&nbsp;You can still buy some quality companies at premium valuations. And, as long as Wall Street holds up the premium valuation, they could return solid returns over the next decade.&nbsp;Turning $50k to $1 million&nbsp;is possible&nbsp;if you periodically put more money into these millionaire-maker stocks and the stars align for them.



<h2>Trade Desk (TTD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/07/ttd_trade_desk_1600-300x169.jpg" alt="The logo for The Trade Desk is displayed on a smart phone."><div>Source: Tada Images / Shutterstock.com</div></div>The Trade Desk&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ttd-stock-quote/">TTD</a>) is a leading advertising technology company that enables advertisers&nbsp;to efficiently target audiences across various digital platforms. In the first quarter, the company posted&nbsp;<a href="https://www.benzinga.com/news/earnings/24/05/38717079/the-trade-desk-reports-strong-q1-results-upbeat-forecast" target="_blank">revenue up 28% year-over-year (YOY) to $491.25 million</a>, beating estimates by $10.76 million.&nbsp;This outperformance is caused by the ongoing shift towards programmatic advertising and the growing adoption of connected TV (CTV).



As&nbsp;more viewers cut the cord and embrace streaming platforms, ad dollars are following suit.&nbsp;The company&rsquo;s partnerships with major players like&nbsp;Disney&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/dis-stock-quote/">DIS</a>),&nbsp;NBCU, and&nbsp;Roku&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/roku-stock-quote/">ROKU</a>) further solidify its position in the CTV space. Additionally, the increasing adoption of UID 2.0 is helping Trade Desk gain market share from walled gardens like Google and Facebook.



With analysts&nbsp;<a href="https://seekingalpha.com/symbol/TTD/earnings/estimates" target="_blank">projecting annual EPS growth of around 25%</a>&nbsp;and sales growth of approximately 20% in the coming years, Trade Desk&nbsp;has the potential to&nbsp;deliver substantial returns for long-term investors. If the stock can maintain its premium valuation, it could&nbsp;very well&nbsp;turn a $50,000 investment into $1 million by 2034.



<h2>ServiceNow (NOW)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/servicenow-now-1600-300x169.jpg" alt="ServiceNow office building in Silicon Valley;"><div>Source: Sundry Photography / Shutterstock.com</div></div>ServiceNow&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/now-stock-quote/">NOW</a>) provides cloud-based software that helps companies manage digital workflows. The company is riding major tailwinds as enterprises race to automate processes and integrate artificial intelligence (AI)&nbsp;across their operations. In Q1, ServiceNow delivered outstanding results, with&nbsp;<a href="https://www.forbes.com/sites/petercohan/2024/04/25/servicenow-stock-drops-4-despite-24-revenue-growth/" target="_blank">subscription revenue growing 24.5%</a>. And, its closely watched current RPO metrics beat guidance.



The company&rsquo;s Generative AI offerings like NowAssist are already the fastest-selling product in&nbsp;company&nbsp;history.



While the stock trades at a premium 55 times forward earnings multiple,&nbsp;this valuation could stick around if ServiceNow sustains its current momentum.&nbsp;With a rock-solid 98%+ renewal rate and&nbsp;<a href="https://seekingalpha.com/symbol/NOW/earnings/estimates" target="_blank">projected 20%+ revenue and EPS growth</a>&nbsp;for years&nbsp;to come, ServiceNow appears well-positioned to do just that.&nbsp;



<h2>MercadoLibre (MELI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/06/meli-1600-300x169.jpg" alt="mercado libre box"><div>Source: tiagogarciafoto / Shutterstock.com</div></div>MercadoLibre&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/meli-stock-quote/">MELI</a>) operates&nbsp;the&nbsp;leading e-commerce and digital payments platform&nbsp;in Latin America.&nbsp;This company is riding&nbsp;powerful&nbsp;megatrends that could propel the stock much higher over the next decade.&nbsp;MercadoLibre is&nbsp;essentially&nbsp;becoming the Amazon of Latin America. Absolutely, it dominates online retail in a region with a rapidly growing middle class and accelerating internet adoption.



While the fintech segment has hit some speed bumps lately due to macro headwinds like high interest rates and softening consumer demand, MercadoLibre&rsquo;s core e-commerce business continues to fire on all cylinders with no signs of cracking. For example, Brazil and Mexico&nbsp;<a href="https://www.investing.com/news/stock-market-news/earnings-call-mercadolibre-reports-robust-q1-growth-in-brazil-mexico-93CH-3419528" target="_blank">posted stellar 30% GMV growth in Q1</a>. Also, the fintech segment has been doing just fine if you zoom out.



<div><a href="https://investorplace.com/wp-content/uploads/2024/06/chart-99.png"><img width="1226" height="741" src="https://investorplace.com/wp-content/uploads/2024/06/chart-99.png" alt="millionaire-maker stocks: Mercado Libre segments growth"> Click to Enlarge</a><div>Source: Chart courtesy of <a href="https://GuruFocus.com">GuruFocus.com</a></div></div>Furthermore, despite challenges in Argentina, MercadoLibre still delivered robust top and bottom-line growth in the quarter. Analysts see EPS skyrocketing&nbsp;<a href="https://seekingalpha.com/symbol/MELI/earnings/estimates" target="_blank">from $34 in 2024 to $245 by 2033</a>. While a 20x return is a tall order, I wouldn&rsquo;t be surprised to see MercadoLibre delivering market-crushing gains.



<h2>DexCom (DXCM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/09/dxcm-stock-1-300x169.jpg" alt="Dexcom (DXCM) logo on an app store page on a mobile phone"><div>Source: FOOTAGE VECTOR PHOTO / Shutterstock.com</div></div>DexCom&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/dxcm-stock-quote/">DXCM</a>) develops and manufactures continuous glucose monitoring systems for diabetes management.&nbsp;The company is riding several&nbsp;powerful&nbsp;megatrends and tailwinds that could propel its stock to massive gains by 2034.



First and foremost, companies in the diabetes treatment space are seeing their revenues and profits surge. With obesity rates remaining stubbornly high and sedentary lifestyles becoming more prevalent, the unfortunate reality is that diabetes cases will likely continue rising for the foreseeable future.&nbsp;This&nbsp;provides a&nbsp;major&nbsp;tailwind for DexCom.



Also, the company posted stellar growth, with&nbsp;<a href="https://www.nasdaq.com/articles/reasons-retain-dexcom-dxcm-stock-your-portfolio-now" target="_blank">revenue growing 24%&nbsp;year-over-year (YOY) to $921 million</a>.&nbsp;In addition, DexCom handily beat expectations on the bottom line, posting EPS of 32 cents versus the 27 cents consensus estimate.



So, although shares have languished in the near term,&nbsp;DXCM remains a good&nbsp;long-term bet.&nbsp;Plus, its EPS&nbsp;is&nbsp;<a href="https://seekingalpha.com/symbol/DXCM/earnings/estimates" target="_blank">expected&nbsp;to more than double</a>&nbsp;in the next four years.



<h2>Safran (SAFRY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/futuristic-engine-rendering-aerospace-300x169.png" alt="An image of a futuristic aerospace engine rendering"><div>Source: solarseven / Shutterstock</div></div>Safran&nbsp;(OTCMKTS:<a href="https://investorplace.com/stock-quotes/safry-stock-quote/">SAFRY</a>) provides aerospace and defense products and services. The aviation industry has been soaring&nbsp;in recent years, fueled by tax cuts that allowed business jet write-offs. While the pandemic temporarily grounded the sector, it&rsquo;s now roaring back with a vengeance. I&rsquo;m not talking about debt-laden airlines, though. I&rsquo;m referring to the real winners: aviation manufacturing and software giants like Safran.



This French powerhouse is posting stellar results, with&nbsp;<a href="https://marketscreener.com/quote/stock/SAFRAN-4696/news/Safran-18-growth-in-quarterly-sales-46542387/" target="_blank">Q1 revenue growing 18% to 6.2 billion euros</a>. Double-digit growth across all divisions&nbsp;was driven&nbsp;by a 27% jump in civil aftermarket sales. Despite a soft start to aircraft production, Safran&nbsp;still&nbsp;expects 10-15% growth in LEAP engine deliveries for 2024.



The real kicker? Safran trades at a mere seven times forward earnings with a juicy 1% dividend yield&nbsp;to boot. As air traffic recovers (narrow body at 113% of 2019 levels, wide body at 94%), Safran is perfectly positioned to ride the aviation megatrend to new heights. Analysts see nothing but upside from here.



<div><a href="https://investorplace.com/wp-content/uploads/2024/06/chart-2024-06-24t173100.666.png"><img width="1226" height="455" src="https://investorplace.com/wp-content/uploads/2024/06/chart-2024-06-24t173100.666.png" alt="SAFRY price targets"> Click to Enlarge</a><div>Source: Chart courtesy of <a href="https://GuruFocus.com">GuruFocus.com</a></div></div><h2>Meituan (MPNGF)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/08/mpngf1600-300x169.jpg" alt="Meituan food delivery on motorbike in Zhongshan China."><div>Source: Freer / Shutterstock.com</div></div>Meituan&nbsp;(OTCMKTS:<a href="https://investorplace.com/stock-quotes/mpngf-stock-quote/">MPNGF</a>) operates China&rsquo;s leading e-commerce platform for services, connecting consumers with local businesses. The company has been among the hardest-hit Chinese stocks in recent years, even with loosening financial policies. 



However, Meituan&rsquo;s latest earnings show signs of a sustained recovery on the horizon. In Q1, revenue&nbsp;<a href="https://www.investing.com/news/stock-market-news/earnings-call-meituan-outlines-robust-q1-growth-with-revenue-up-75-93CH-3474359" target="_blank">surged 75% YOY to 73.3 billion RMB</a>, while adjusted net profit jumped 36.4% to 7.5 billion RMB.&nbsp;User&nbsp;base&nbsp;and merchant base growth accelerated for the fourth&nbsp;straight&nbsp;quarter, both hitting record highs.



In fact,&nbsp;Meituan is well-positioned to capitalize on the megatrend of digitizing local commerce in China.&nbsp;The company&nbsp;is innovating&nbsp;with new models like Branded Satellite Stores and&nbsp;elevating&nbsp;consumer experience with initiatives like Pin Hao Fan.&nbsp;Analysts expect&nbsp;<a href="https://seekingalpha.com/symbol/MPNGY/earnings/estimates" target="_blank">EPS to increase from 46 cents this year to nearly 80&nbsp;cents&nbsp;in 2025</a>. While multibagger returns by 2034 would require cooperation from the broader Chinese market, Meituan&rsquo;s stock has&nbsp;already nearly&nbsp;doubled off January lows.&nbsp;If it can sustain high-profit growth,&nbsp;this rebound is just&nbsp;getting started.



<h2>Workday (WDAY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/09/wday-stock-1-300x169.jpg" alt="Workday Layoffs. A close-up view of a Workday (WDAY Stock) sign in Pleasanton, California."><div>Source: Sundry Photography / Shutterstock.com</div></div>Workday&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/wday-stock-quote/">WDAY</a>) provides enterprise cloud applications for finance and human resources.&nbsp;This company is well-positioned to benefit from the growing trend of workforce automation, particularly among large enterprises looking to streamline operations.



As more companies embrace digital transformation and seek to optimize their HR and financial processes, demand for Workday&rsquo;s solutions should remain robust. The company posted&nbsp;<a target="_blank" href="https://fortune.com/2024/06/07/workday-cfo-revenue-fortune-500-debut/">19% subscription revenue growth</a>&nbsp;in Q1.



However, investors must weigh the risks. The rise of AI could be a double-edged sword. While it may drive more companies to adopt Workday&rsquo;s automation tools,&nbsp;it could also lead to significant headcount reductions that shrink Workday&rsquo;s addressable market. Additionally, with the stock&rsquo;s muted performance in recent years, a 20x return by 2034, while not impossible, would require a near-perfect execution.&nbsp;Nevertheless,&nbsp;I still think&nbsp;it is a good candidate since it has strong tailwinds, and analysts expect solid growth going forward.



On the date of publication, Omor Ibne Ehsan did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines.</a>
<div>Omor Ibne Ehsan is a writer at InvestorPlace. He is a self-taught investor with a focus on growth and cyclical stocks that have strong fundamentals, value, and long-term potential. He also has an interest in high-risk, high-reward investments such as cryptocurrencies and penny stocks. You can follow him on <a href="https://www.linkedin.com/in/omor-ibne-ehsan-56068022b/">LinkedIn</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/06/have-50k-7-stocks-to-buy-to-retire-with-1-million-by-2034/">Have $50K? 7 Stocks to Buy to Retire With $1 Million by 2034</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Have $50K? 7 Stocks to Buy to Retire With $1 Million by 2034

How is QQQ stock faring? The Invesco QQQ ETF is up 0.09% in the past 5 days and has risen about 17.3% year-to-date. &nbsp; According to TipRanks' u...

QQQ ETF Update, 7/2/2024

DexCom's ADA Conference Takeaways: Stelo, CGM Tailwinds Still Intact

How is QQQ stock faring? The Invesco QQQ ETF is up 2.48% in the past 5 days and has risen about 18% year-to-date. &nbsp; According to TipRanks' uni...

QQQ ETF Update, 7/4/2024

Focus on healthcare has increased since the COVID-19 pandemic caused massive disruptions. Several healthcare companies are expected to benefit from...

ISRG, PFE, or DXCM: Which Healthcare Stock Could Generate the Highest Returns?

CSGP

ILMN

ISRG

KLAC

MELI

MPNGF

PODD

SAFRY

TNDM

VRSK

WDAY

Press Releases

Dexcom Announces Upcoming Conference Presentation

Stelo by Dexcom First Glucose Biosensor to be Cleared by FDA as Over-the-Counter

Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 4:30 p.m. Eastern Time

Dexcom Publishes Annual Sustainability Report

Dexcom Reports First Quarter 2024 Financial Results

Tandem Mobi Insulin Pump Now Compatible with Dexcom G7 CGM

Dexcom G7 Now Connects Directly to Apple Watch in the U.S.

Dexcom Showcases Extensive Clinical Data at ADA 2024 Demonstrating the Benefit of Dexcom CGM Use Among People With Type 2 Diabetes

Dexcom Schedules Second Quarter 2024 Earnings Release and Conference Call for July 25, 2024 at 4:30 p.m. Eastern Time.

Abbott Laboratories

Baxter Intl


Josh GottheimerHouse (D-NJ)	$1K - $15K	stock	Sale	Oct 15, 2023	Sep 12, 2023	House
Josh GottheimerHouse (D-NJ)	$1K - $15K	stock	Sale (Partial)	Sep 16, 2023	Aug 21, 2023	House
Josh GottheimerHouse (D-NJ)	$1K - $15K	stock	Sale (Partial)	Oct 16, 2022	Sep 28, 2022	House

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Government Trades

DexCom Inc

top performing DXCM trades